- Previous Close
889.00 - Open
885.00 - Bid 874.00 x --
- Ask 880.00 x --
- Day's Range
872.00 - 888.00 - 52 Week Range
730.00 - 969.00 - Volume
381 - Avg. Volume
933 - Market Cap (intraday)
3.932B - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
24.57 - EPS (TTM)
35.61 - Earnings Date Mar 26, 2025 - Mar 31, 2025
- Forward Dividend & Yield 14.50 (1.91%)
- Ex-Dividend Date Jun 12, 2024
- 1y Target Est
901.00
NEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland. It operates through Wholesale Distribution of Medicines, Manufacture of Pharmaceuticals, Medical Operator, Clinical Trials, and Insurance Activities segments. The company owns and produces Rx, OTC medicines, dietary supplements, medical devices, dermocosmetics, hygiene products, personal protective equipment, as well as diagnostic and dressing materials under the Swiat Zdrowia, APTEO, GENOPTIM, CERA+ Solutions, and Kic Kic brand names to pharmacists, medical doctors, and patients. It provides medical care services, including prevention, diagnostics, treatment, and complementary services; and financing services, such as insurance, subscriptions, occupational medicine, preventive and medicine programmes, FFS, NFZ, public, private, and corporate payer services. In addition, the company offers TPA services, remote consultations, stationary visits, diagnostic tests, and occupational medicine services; operates a medical helpline and medical facilities; and offers medicine through apteline.pl, an e-commerce medical ordering site. Further, it engages in running clinical trials in the field of outsourcing clinical research and conducting clinical research centres; provision of insurance activities, including health insurance products. It also provides advertising and marketing services to pharmaceutical market entities; and logistics services for pharmaceutical manufacturers. The company was formerly known as Torfarm SA and changed its name to NEUCA S.A. in April 2010. NEUCA S.A. was founded in 1990 and is based in Torun, Poland.
www.neuca.pl4,633
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NEU.WA
View MorePerformance Overview: NEU.WA
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NEU.WA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NEU.WA
View MoreValuation Measures
Market Cap
3.93B
Enterprise Value
4.12B
Trailing P/E
24.59
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.32
Price/Book (mrq)
3.58
Enterprise Value/Revenue
0.33
Enterprise Value/EBITDA
9.91
Financial Highlights
Profitability and Income Statement
Profit Margin
1.36%
Return on Assets (ttm)
3.61%
Return on Equity (ttm)
17.24%
Revenue (ttm)
12.13B
Net Income Avi to Common (ttm)
164.59M
Diluted EPS (ttm)
35.61
Balance Sheet and Cash Flow
Total Cash (mrq)
119.27M
Total Debt/Equity (mrq)
54.74%
Levered Free Cash Flow (ttm)
65.11M